Guest guest Posted March 10, 2009 Report Share Posted March 10, 2009 LINK U.S. Patent Documents 3654090 April 1972 Schuurs et al. Primary Examiner: Tanenholtz; Alvin E. Assistant Examiner: Hensley; Max D. Attorney, Agent or Firm: Weisberger; Hugo E. http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1 & Sect2=HITOFF & p=1 & u=%2Fnetahtml%2FPTO%2Fsearch-bool.html & r=1 & f=G & l=50 & d=PALL & RefSrch=yes & Query=PN%2F3791932 [[...For the demonstration and determination of substances playing a prominent part in biochemical processes, i.e. low molecular substances, such as vitamins and steroids, or high molecular ones, such as proteins and carbohydrates, it is often possible to employ reactions of these substances with proteins having a specific binding affinity for these substances. Thus, it is possible to determine the concentration of a steroid by employing a protein capable of binding this steroid specifically. As examples of such combinations are mentioned cortisol and transcortin, 17.beta.-oestradiol and the oestradiol-binding receptor protein of the uterus. It is also possible to link a low molecular substance chemically with a protein, and to inject this conjugate into a test animal, which then reacts by forming antibodies against, among others, the low molecular substance. The latter is in this case to be regarded as a socalled hapten. The antibodies against the hapten may be regarded as a special case of specific binding proteins...]] My inference from this is that any 'drug'/protein combination in humans will produce an antibody reaction..... so, especially with fluorinated drugs, there will almost certainly be a an antibody reaction to all such combinations in human use. but I'm only a sceptic Bob Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.